Asset
MIRICORILANT
Corcept Therapeutics Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03878264 | phase1 | completed | 2018-08-06 | 2019-03-24 | Corcept Therapeutics | Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants |
| NCT03315338 | phase1 | completed | 2017-09-15 | 2019-02-22 | Corcept Therapeutics | First-in-human Study in Healthy Subjects |
| NCT03877562 | phase1 | completed | 2019-04-01 | 2020-03-13 | Corcept Therapeutics | The Effect of CORT118335 on Olanzapine-Induced Weight Gain |
FDA applications (0)
This company has no applications containing this asset.